Faculty members in Penn Medicine's Pulmonary Division, led by Steven Albelda, MD, interact closely with faculty from thoracic surgery, oncology and pathology to conduct cutting-edge diagnostic and therapeutic investigations related to lung cancer and malignant mesothelioma.
Members of the group include:
Research from this group is supported by an NCI-funded program project, and a grant from the Pennsylvania Department of Health and Foundation.
Specific faculty interests include:
- Preclinical studies of immunogene therapy for lung cancer and mesothelioma
- Immune analysis of clinical trials using gene therapy or immunotherapy
- Mesothelioma and cancer genomics
- Personalized medicine
- Clinical trials using gene therapy or immunotherapy to treat malignant mesothelioma and lung cancer
- Interventional bronchoscopy treatment of COPD
- Determination of markers to predict survival after lung cancer surgery
- Discovery of biomarkers for early detection of lung cancer
- Gene environment interactions in lung cancer
- Combining surgery with immunotherapy
Melpo Christofidou-Solomidou, PhD
- Chemoprevention of lung carcinogenesis and evaluation of anti-carcinogenic effects of common botanicals